Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
News|Articles|May 2, 2005
- Pharmaceutical Technology-05-02-2005
- Volume 29
- Issue 5
High Molecular Weight Polyethylene Oxide-Based Drug Delivery Systems - Part I: Hydrogels and Hydrophilic Matrix Systems
The authors review the solution and powder properties of polyethylene oxide and its various applications in hydrogels and hydrophilic matrix systems.
Advertisement
Articles in this issue
over 21 years ago
New Vaccine Technologies Carry and Deliver by Kaylynn Chiarelloover 21 years ago
GenerationNextover 21 years ago
New Vaccine Technologies Carry and Deliverover 21 years ago
May 2005over 21 years ago
Bar Coding Deadline Loomsover 21 years ago
In the Spotlight - May 2005over 21 years ago
New FDA Policies Shape Pharma Development and Productionover 21 years ago
Automating HPLC and GC Analytical Method Validationover 21 years ago
Price MattersAdvertisement
Related to this article
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
Improving Oral Peptide Delivery Through Structural Modifications
4
Who Answers for Your Data? Building a Life Sciences Data Mesh
5